Skip to main content
. 2002 Feb 1;86(3):402–408. doi: 10.1038/sj.bjc.6600072

Figure 2.

Figure 2

Recurrence-free interval curves for groups of breast cancer patients (A) with and without overexpression of cyclin A, and (B) OR-positive breast cancer treated with tamoxifen, with and without overexpression of cyclin A (log rank P value=0.0462).